Compare · ARGX vs PRME
ARGX vs PRME
Side-by-side comparison of argenx SE (ARGX) and Prime Medicine Inc. (PRME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and PRME operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $56.99B, about 107.0x PRME ($532.8M).
- Over the past year, ARGX is up 53.0% and PRME is down 26.7% - ARGX leads by 79.7 points.
- ARGX has been more active in the news (6 items in the past 4 weeks vs 3 for PRME).
- ARGX has more recent analyst coverage (25 ratings vs 16 for PRME).
- Company
- argenx SE
- Prime Medicine Inc.
- Price
- $910.67-0.90%
- $2.98+1.36%
- Market cap
- $56.99B
- $532.8M
- 1M return
- +2.44%
- -5.83%
- 1Y return
- +53.03%
- -26.72%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2022
- News (4w)
- 6
- 3
- Recent ratings
- 25
- 16
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
- argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline
- SEC Form 6-K filed by argenx SE
- argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
Latest PRME
- Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
- Prime Medicine Inc. filed SEC Form 8-K: Other Events
- Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
- Prime Medicine upgraded by H.C. Wainwright with a new price target
- Prime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
- Prime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
- SEC Form 4 filed by Director Schenkein David P
- SEC Form 4 filed by Director Marrazzo Jeffrey D
- SEC Form 4 filed by Director Nelsen Robert
- SEC Form 4 filed by Director Kelly Michael Aaron